XML 26 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Note 7 - Share-based Compensation
9 Months Ended
Sep. 30, 2021
Notes to Financial Statements  
Share-based Payment Arrangement [Text Block]

7.

Share-based Compensation

 

The Company has one active stock incentive plan for employees and directors, the 2007 Stock Incentive Plan, which provides for awards of stock options to purchase shares of common stock, stock appreciation rights, restricted and unrestricted shares of common stock, restricted stock units (“RSUs”), and performance share awards (“PSAs”).

 

The Company recognizes the compensation cost of employee and director services received in exchange for awards of equity instruments based on the grant date estimated fair value of the awards. The Company estimates the fair value of RSUs and PSAs using the value of the Company’s stock on the date of grant. Share-based compensation cost is recognized over the period during which the employee or director is required to provide service in exchange for the award and, as forfeitures occur, the associated compensation cost recognized to date is reversed. For awards with performance-based payout conditions, the Company recognizes compensation cost based on the probability of achieving the performance conditions, with changes in expectations recognized as an adjustment to earnings in the period of change. Any recognized compensation cost is reversed if the conditions are ultimately not met.

 

The following table summarizes share-based compensation expense recorded (in thousands):

 

   

Three Months Ended September 30,

   

Nine Months Ended September 30,

 
   

2021

   

2020

   

2021

   

2020

 
                                 

Cost of sales

  $ 202     $ 255     $ 685     $ 576  

Selling, general, and administrative expense

    395       618       1,752       1,730  

Total

  $ 597     $ 873     $ 2,437     $ 2,306  

 

Restricted Stock Units and Performance Share Awards

 

The Company’s stock incentive plan provides for equity instruments, such as RSUs and PSAs, which grant the right to receive a specified number of shares over a specified period of time. RSUs are service-based awards and vest according to vesting schedules, which range from immediate to ratably over a three-year period. PSAs are service-based awards that vest according to the terms of the grant and have performance-based payout conditions.

 

The following table summarizes the Company’s RSU and PSA activity:

 

   

Number of RSUs and PSAs (1)

   

Weighted-Average Grant Date Fair Value

 
                 

Unvested RSUs and PSAs as of December 31, 2020

    129,572     $ 25.86  

RSUs and PSAs granted

    90,368       33.30  

RSUs and PSAs vested (2)

    (58,809

)

    25.53  

Unvested RSUs and PSAs as of September 30, 2021

    161,131       30.26  

 

(1)

The number of PSAs disclosed in this table are at the target level of 100%.

   

(2)

For the PSAs vested on March 31, 2021, the actual number of common shares that were issued was determined by multiplying the PSAs by a payout percentage based on the performance-based conditions achieved. The payout percentage was 126% for the 2019-2020 performance period and 200% for the 2020 performance period.

 

The unvested balance of RSUs and PSAs as of September 30, 2021 includes approximately 116,000 PSAs. The vesting of these awards is subject to the achievement of specified performance-based conditions, and the actual number of common shares that will ultimately be issued will be determined by multiplying this number of PSAs by a payout percentage ranging from 0% to 200%.

 

As of September 30, 2021, unrecognized compensation expense related to the unvested portion of the Company’s RSUs and PSAs was $3.3 million, which is expected to be recognized over a weighted-average period of 1.7 years.

 

Stock Awards

 

For the nine months ended September 30, 2021 and 2020, stock awards of 12,606 shares and 17,442 shares, respectively, were granted to non-employee directors, which vested immediately upon issuance. The Company recorded compensation expense based on the weighted-average fair market value per share of the awards on the grant date of $30.94 in 2021 and $25.81 in 2020.